These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 33016804)
21. A strategy to reduce cumulative anthracycline exposure in low-risk pediatric acute myeloid leukemia while maintaining favorable outcomes. Sabnis HS; Minson KA; Monroe C; Allen K; Metts JL; Cooper TM; Woods WG; Castellino SM; Keller FG Leuk Res; 2020 Sep; 96():106421. PubMed ID: 32683126 [TBL] [Abstract][Full Text] [Related]
22. Minimal residual disease may be an early prognostic indicator for newly diagnosed acute myeloid leukemia patients induced by decitabine-based chemotherapy. Tan Y; Fu Y; Liu C; Sun J; Liu S; Lin H; Liu Q; Yang Y; Li Y; Su L; Gao S Hematology; 2019 Dec; 24(1):552-558. PubMed ID: 31315553 [No Abstract] [Full Text] [Related]
23. Homoharringtonine enhances cytarabine-induced apoptosis in acute myeloid leukaemia by regulating the p38 MAPK/H2AX/Mcl-1 axis. Qiu Y; Bai L; Zhao H; Mei X BMC Cancer; 2024 Apr; 24(1):520. PubMed ID: 38658865 [TBL] [Abstract][Full Text] [Related]
24. [Prognosis and chromosomal abnormalities in 79 children with t (8;21) acute myeloid leukemia]. Chen YM; Liu TF; Ruan M; Zou Y; Chen XJ; Guo Y; Wang SC; Zhu XF Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2009 Oct; 31(5):542-6. PubMed ID: 19968066 [TBL] [Abstract][Full Text] [Related]
25. Attempts to optimize postinduction treatment in childhood acute myeloid leukemia without core-binding factors: A report from the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG). Hasegawa D; Tawa A; Tomizawa D; Watanabe T; Saito AM; Kudo K; Taga T; Iwamoto S; Shimada A; Terui K; Moritake H; Kinoshita A; Takahashi H; Nakayama H; Koh K; Goto H; Kosaka Y; Miyachi H; Horibe K; Nakahata T; Adachi S Pediatr Blood Cancer; 2020 Dec; 67(12):e28692. PubMed ID: 32886449 [TBL] [Abstract][Full Text] [Related]
26. Long-term outcomes of de novo acute myeloid leukemia in Thai patients. Niparuck P; Chuncharunee S; Ungkanont A; Udomtrupayakul U; Aungchaisuksiri P; Rerkamnuatchoke B; Jootar S; Atichartakarn V J Med Assoc Thai; 2009 Sep; 92(9):1143-9. PubMed ID: 19772172 [TBL] [Abstract][Full Text] [Related]
27. Homoharringtonine deregulates Chen XJ; Zhang WN; Chen B; Xi WD; Lu Y; Huang JY; Wang YY; Long J; Wu SF; Zhang YX; Wang S; Li SX; Yin T; Lu M; Xi XD; Li JM; Wang KK; Chen Z; Chen SJ Proc Natl Acad Sci U S A; 2019 Feb; 116(6):2220-2225. PubMed ID: 30659143 [TBL] [Abstract][Full Text] [Related]
28. [Clinical study on combination of homoharringtonine, Ara-C and idarubicin induction for treatment of newly diagnosed acute myeloid leukemia patients]. Qin TJ; Xu ZF; Fang LW; Zhang HL; Zhang Y; Wang JZ; Pan LJ; Hu NB; Xiao ZJ Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Oct; 19(5):1277-82. PubMed ID: 22040988 [TBL] [Abstract][Full Text] [Related]
29. [Outcome of acute promyelocytic leukemia with homoharringtonine (HHT) and ATRA]. Yuan Y; Li W; Lin D; Mi YC; Wang Y; Wei H; Liu BC; Zhou CL; Liu KQ; Wang JY; Wei SN; Gong BF; Zhao XL; Sun MY; Wan JX Zhonghua Xue Ye Xue Za Zhi; 2011 Nov; 32(11):752-7. PubMed ID: 22339911 [TBL] [Abstract][Full Text] [Related]
30. Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: the AML99 trial from the Japanese Childhood AML Cooperative Study Group. Tsukimoto I; Tawa A; Horibe K; Tabuchi K; Kigasawa H; Tsuchida M; Yabe H; Nakayama H; Kudo K; Kobayashi R; Hamamoto K; Imaizumi M; Morimoto A; Tsuchiya S; Hanada R J Clin Oncol; 2009 Aug; 27(24):4007-13. PubMed ID: 19620491 [TBL] [Abstract][Full Text] [Related]
31. A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia: the Japan Adult Leukemia Study Group AML 97 Study. Miyawaki S; Sakamaki H; Ohtake S; Emi N; Yagasaki F; Mitani K; Matsuda S; Kishimoto Y; Miyazaki Y; Asou N; Matsushima T; Takahashi M; Ogawa Y; Honda S; Ohno R; Cancer; 2005 Dec; 104(12):2726-34. PubMed ID: 16284985 [TBL] [Abstract][Full Text] [Related]
32. Pediatric Oncology Group (POG) studies of acute myeloid leukemia (AML): a review of four consecutive childhood AML trials conducted between 1981 and 2000. Ravindranath Y; Chang M; Steuber CP; Becton D; Dahl G; Civin C; Camitta B; Carroll A; Raimondi SC; Weinstein HJ; Leukemia; 2005 Dec; 19(12):2101-16. PubMed ID: 16136167 [TBL] [Abstract][Full Text] [Related]
33. Experience with 2-chlorodeoxyadenosine in previously untreated children with newly diagnosed acute myeloid leukemia and myelodysplastic diseases. Krance RA; Hurwitz CA; Head DR; Raimondi SC; Behm FG; Crews KR; Srivastava DK; Mahmoud H; Roberts WM; Tong X; Blakley RL; Ribeiro RC J Clin Oncol; 2001 Jun; 19(11):2804-11. PubMed ID: 11387351 [TBL] [Abstract][Full Text] [Related]
34. Homoharringtonine, aclarubicin and cytarabine (HAA) regimen as the first course of induction therapy is highly effective for acute myeloid leukemia with t (8;21). Zhu HH; Jiang H; Jiang Q; Jia JS; Qin YZ; Huang XJ Leuk Res; 2016 May; 44():40-4. PubMed ID: 26994850 [TBL] [Abstract][Full Text] [Related]
35. Homoharringtonine potentiates the antileukemic activity of arsenic trioxide against acute myeloid leukemia cells. Chen P; Zhan W; Wang B; You P; Jin Q; Hou D; Wang X; You R; Zou H; Chen Y; Huang H Exp Cell Res; 2019 Mar; 376(2):114-123. PubMed ID: 30763586 [TBL] [Abstract][Full Text] [Related]
36. Efficacy of common salvage chemotherapy regimens in patients with refractory or relapsed acute myeloid leukemia: A retrospective cohort study. Xu J; Lv TT; Zhou XF; Huang Y; Liu DD; Yuan GL Medicine (Baltimore); 2018 Sep; 97(39):e12102. PubMed ID: 30278488 [TBL] [Abstract][Full Text] [Related]
37. [Long-term follow-up of treatment outcome and prognosis on 46 children with acute promyelocytic leukemia]. Xu XJ; Shi SW; Tang YM; Song H; Yang SL; Wei J; Xu WQ; Pan BH; Chen YH; Zhao FY; Shen HQ; Qian BQ; Zhang LY; Ning BT Zhongguo Dang Dai Er Ke Za Zhi; 2007 Feb; 9(1):28-33. PubMed ID: 17306073 [TBL] [Abstract][Full Text] [Related]
38. Outpatient ADE (cytarabine, daunorubicin, and etoposide) is feasible and effective for the first relapse of pediatric acute myeloid leukemia: A prospective, phase II study. Garg A; Ganguly S; Vishnubhatla S; Chopra A; Bakhshi S Pediatr Blood Cancer; 2020 Sep; 67(9):e28404. PubMed ID: 32672904 [TBL] [Abstract][Full Text] [Related]
39. HAG regimen improves survival in adult patients with hypocellular acute myeloid leukemia. Hu X; Fu W; Wang L; Gao L; Lü S; Xi H; Qiu H; Chen L; Chen J; Ni X; Xu X; Zhang W; Yang J; Wang J; Song X Oncotarget; 2016 Jan; 7(3):3623-34. PubMed ID: 26497216 [TBL] [Abstract][Full Text] [Related]
40. Homoharringtonine synergy with oridonin in treatment of t(8; 21) acute myeloid leukemia. Zhang W; Lu Y; Zhen T; Chen X; Zhang M; Liu P; Weng X; Chen B; Wang Y Front Med; 2019 Jun; 13(3):388-397. PubMed ID: 30206768 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]